Are the New Kawasaki-like Syndromes in the Children Associated with COVID-19?

Abstract

COVID-19 pandemic is severe acute respiratory syndrome is still ongoing since December in almost every countries and cities. This syndrome was first reported in December 2019 in Wuhan, China than first case was seen in Thailand and many COVID-19 cases are detected in all populations, and most of them recovered and age, comorbidities, gender, of COVID-19 deaths and the severity of the infection were changed according to the patients’ additional health risk parameters. Elderly population and people with chronic diseases have been categorized as major risk group, however some COVID-19 positive children have showed Kawasaki disease-like syndromes such as hyper-inflammatory state according to the current state same as adult patients infected by COVID-19. We suggested that glucose-6-phosphate dehydrogenase (G6PD) deficiency can make some children more vulnerable against COVID-19 infection same as adults, since this virus attacks hemoglobin and heme metabolism leading to the increased hemolysis and impaired oxygen transport to the tissues. G6PD deficiency is most affects males. Thus, possible correlation between COVID-19 infection and Kawasaki disease like syndromes in the especially male children should be further investigated and maybe children may be categorized as risk group in the future.

Keywords

• COVID-19
• pandemic
• hyper-inflammatory state
• Kawasaki disease
• G6PD deficiency

References

1. [1] Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine 2020;383:2439–50. https://doi.org/10.1056/NEJMoa2027906.
2. [2] Aydemir D, Ulusu NN. Are Angiotensin II Receptor Blockers for Hypertension a Gleam of Hope or not Against COVID-19 Infection? The Journal of Basic and Clinical Health Sciences 2020. https://doi.org/10.30621/jbachs.2020.1153.
3. [3] Aydemir D, Ulusu NN. People with blood disorders can be more vulnerable during COVID-19 pandemic: A hypothesis paper. Transfusion and Apheresis Science 2021;60:103080. https://doi.org/10.1016/j.transci.2021.103080.
4. [4] Aydemir D, Ulusu NN. Influence of Lifestyle Parameters – Dietary Habit, Chronic Stress and Environmental Factors, Jobs – on the Human Health in Relation to the COVID-19 Pandemic. Disaster Medicine and Public Health Preparedness 2020;14:e36–7. https://doi.org/10.1017/dmp.2020.222.
5. [5] Aydemir D, Ulusu NN. Correspondence: Angiotensin-converting enzyme 2 coated nanoparticles containing respiratory masks, chewing gums and nasal filters may be used for protection against COVID-19 infection. Travel Medicine and Infectious Disease 2020;37:101697. https://doi.org/10.1016/j.tmaid.2020.101697.
6. [6] Aydemir D, Dağlıoğlu G, Candevir A, Kurtaran B, Bozdogan ST, Inal TC, et al. COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients. Nucleosides, Nucleotides & Nucleic Acids 2021;40:505–17. https://doi.org/10.1080/15257770.2021.1897457.
7. [7] Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020:m1086. https://doi.org/10.1136/bmj.m1086.
8. [8] Aydemir D, Ulusu NN. Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths? Pathogens and Global Health 2020;114:109–10. https://doi.org/10.1080/20477724.2020.1751388.

9. [9] Aydemir D, Ulusu NN. Commentary: Challenges for PhD students during COVID ‐19 pandemic: Turning crisis into an opportunity. Biochemistry and Molecular Biology Education 2020;48:428–9. https://doi.org/10.1002/bmb.21351.
10. [10] Cherqaoui B, Koné-Paut I, Yager H, Bourgeois F le, Piram M. Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review. Rheumatology 2021;60:4530–7. https://doi.org/10.1093/rheumatology/keab026.
11. [11] Mihai C, Chisnoiu T, Cambrea C, Frecus C, Mihai L, Balasa A, et al. Neurological manifestations found in children with multisystem inflammatory syndrome. Experimental and Therapeutic Medicine 2022;23:261. https://doi.org/10.3892/etm.2022.11187.
12. [12] Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatology International 2021;41:19–32. https://doi.org/10.1007/s00296-020-04749-4.
13. [13] Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease. Clinical and Experimental Immunology 2011;164:20–2. https://doi.org/10.1111/j.1365-2249.2011.04361.x.
14. [14] Johnson RM, Little JR, Storch GA. Kawasaki-Like Syndromes Associated with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 2001;32:1628–34. https://doi.org/10.1086/320523.
15. [15] Ulusu NN. Glucose-6-phosphate dehydrogenase deficiency and Alzheimer’s disease: Partners in crime? The hypothesis. Medical Hypotheses 2015;85:219–23. https://doi.org/10.1016/j.mehy.2015.05.006.
16. [16] Obeidat HR, Al-Dossary S, Asseri A. Kawasaki disease with Glucose-6-Phosphate Dehydrogenase deficiency, case report. Saudi Pharmaceutical Journal 2015;23:455–7. https://doi.org/10.1016/j.jsps.2014.11.003.
17. [17] Horikoshi N, Hwang S, Gati C, Matsui T, Castillo-Orellana C, Raub AG, et al. Long-range structural defects by pathogenic mutations in most severe glucose-6-phosphate dehydrogenase deficiency. Proceedings of the National Academy of Sciences 2021;118. https://doi.org/10.1073/pnas.2022790118.
18. [18] Dabboubi R, Amri Y, Hamdi S, Jouini H, Sahli C, Fredj SH, et al. Glucose-6-phosphate dehydrogenase deficiency in Tunisian jaundiced neonates. Annales de Biologie Clinique 2020;78:411–6. https://doi.org/10.1684/abc.2020.1558.
19. [19] Luzzatto L, Nannelli C, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematology/Oncology Clinics of North America 2016;30:373–93. https://doi.org/10.1016/j.hoc.2015.11.006.
20. [20] Ulusu NN, Gok M, Erman B, Turan B. Effects of timolol treatment on pancreatic antioxidant enzymes in streptozotocin-induced diabetic rats: An experimental and computational study. Journal of Medical Biochemistry 2019;38:306–16. https://doi.org/10.2478/jomb-2018-0034.
21. [21] Ulusu NN. Glucose-6-phosphate dehydrogenase deficiency and Alzheimer’s disease: Partners in crime? The hypothesis. Medical Hypotheses 2015;85:219–23. https://doi.org/10.1016/j.mehy.2015.05.006.
22. [22] Zhang Q, Ni Y, Wang S, Agbana YL, Han Q, Liu W, et al. G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression. International Journal of Medical Sciences 2022;19:47–64. https://doi.org/10.7150/ijms.58902.
23. [23] Chen P-H, Tjong W-Y, Yang H-C, Liu H-Y, Stern A, Chiu DT-Y. Glucose-6-Phosphate Dehydrogenase, Redox Homeostasis and Embryogenesis. International Journal of Molecular Sciences 2022;23:2017. https://doi.org/10.3390/ijms23042017.
24. [24] Ho H, Cheng M, Chiu DT. Glucose-6-phosphate dehydrogenase – from oxidative stress to cellular functions and degenerative diseases. Redox Report 2007;12:109–18. https://doi.org/10.1179/135100007X200209.
25. [25] Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clinical Immunology 2020;219:108544. https://doi.org/10.1016/j.clim.2020.108544.
26. [26] Ulusu NN. Evolution of Enzyme Kinetic Mechanisms. Journal of Molecular Evolution 2015;80:251–7. https://doi.org/10.1007/s00239-015-9681-0.
27. [27] Ulusu NN. Curious Cases of the Enzymes / Neobiča Istorija Enzima. Journal of Medical Biochemistry 2015;34:271–81. https://doi.org/10.2478/jomb-2014-0045.
28. [28] Tandogan B, Kuruüzüm-Uz A, Sengezer C, Güvenalp Z, Demirezer LÖ, Nuray Ulusu N. In vitro effects of rosmarinic acid on glutathione reductase and glucose 6-phosphate dehydrogenase. Pharmaceutical Biology 2011;49:587–94. https://doi.org/10.3109/13880209.2010.533187.
29. [29] Ulusu NN. Glucose-6-phosphate dehydrogenase deficiency and Alzheimer’s disease: Partners in crime? The hypothesis. Medical Hypotheses 2015;85:219–23. https://doi.org/10.1016/j.mehy.2015.05.006.
30. [30] Boonyuen U, Chamchoy K, Swangsri T, Saralamba N, Day NPJ, Imwong M. Detailed functional analysis of two clinical glucose-6-phosphate dehydrogenase (G6PD) variants, G6PDViangchan and G6PDViangchan+Mahidol: Decreased stability and catalytic efficiency contribute to the clinical phenotype. Molecular Genetics and Metabolism 2016;118:84–91. https://doi.org/10.1016/j.ymgme.2016.03.008.
31. [31] Sodeinde O. Glucose-6-phosphate dehydrogenase deficiency. Baillière’s Clinical Haematology 1992;5:367–82. https://doi.org/10.1016/S0950-3536(11)80024-7.
32. [32] Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and Gender-Based Differences in COVID-19. Frontiers in Public Health 2020;8. https://doi.org/10.3389/fpubh.2020.00418.
33. [33] Aydemir D, Ulusu NN. People with blood disorders can be more vulnerable during COVID-19 pandemic: A hypothesis paper. Transfusion and Apheresis Science 2021;60:103080. https://doi.org/10.1016/j.transci.2021.103080.
34. [34] Aydemir D, Ulusu NN. Are Angiotensin II Receptor Blockers for Hypertension a Gleam of Hope or not Against COVID-19 Infection? The Journal of Basic and Clinical Health Sciences 2020. https://doi.org/10.30621/jbachs.2020.1153.
35. [35] Aydemir D, Dağlıoğlu G, Candevir A, Kurtaran B, Bozdogan ST, Inal TC, et al. COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients. Nucleosides, Nucleotides & Nucleic Acids 2021;40:505–17. https://doi.org/10.1080/15257770.2021.1897457.
36. [36] Chen C-H, Lin L-Y, Yang KD, Hsieh K-S, Kuo H-C. Kawasaki disease with G6PD deficiency—Report of one case and literature Review. Journal of Microbiology, Immunology and Infection 2014;47:261–3. https://doi.org/10.1016/j.jmii.2012.05.002.
37. [37] Aydemir D, Ulusu NN. Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths? Pathogens and Global Health 2020;114:109–10. https://doi.org/10.1080/20477724.2020.1751388.
38. [38] Aydemir D, Ulusu NN. Are Angiotensin II Receptor Blockers for Hypertension a Gleam of Hope or not Against COVID-19 Infection? The Journal of Basic and Clinical Health Sciences 2020. https://doi.org/10.30621/jbachs.2020.1153.
39. [39] Aydemir D, Ulusu NN. Correspondence: Importance of the validated serum biochemistry and hemogram parameters for rapid diagnosis and to prevent false negative results during COVID‐19 pandemic. Biotechnology and Applied Biochemistry 2021;68:390–1. https://doi.org/10.1002/bab.1936.
40. [40] Aydemir D, Dağlıoğlu G, Candevir A, Kurtaran B, Bozdogan ST, Inal TC, et al. COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients. Nucleosides, Nucleotides & Nucleic Acids 2021;40:505–17. https://doi.org/10.1080/15257770.2021.1897457.
41. [41] Russo A, Tellone E, Barreca D, Ficarra S, Laganà G. Implication of COVID-19 on Erythrocytes Functionality: Red Blood Cell Biochemical Implications and Morpho-Functional Aspects. International Journal of Molecular Sciences 2022;23:2171. https://doi.org/10.3390/ijms23042171.
42. [42] Jamerson BD, Haryadi TH, Bohannon A. Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19? Archives of Medical Research 2020;51:743–4. https://doi.org/10.1016/j.arcmed.2020.06.006.
43. [43] Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease. Clinical and Experimental Immunology 2011;164:20–2. https://doi.org/10.1111/j.1365-2249.2011.04361.x.
44. [44] Sato W, Yokouchi Y, Oharaseki T, Asakawa N, Takahashi K. The pathology of Kawasaki disease aortitis: a study of 37 cases. Cardiovascular Pathology 2021;51:107303. https://doi.org/10.1016/j.carpath.2020.107303.
45. [45] Qin Q, Wang D, Xu L, Lan Y, Tong M. Evaluating Lymph Node Stiffness to Differentiate Bacterial Cervical Lymphadenitis and Lymph Node–First Presentation of Kawasaki Disease by Shear Wave Elastography. Journal of Ultrasound in Medicine 2021;40:1371–80. https://doi.org/10.1002/jum.15518.
46. [46] Marrani E, Burns JC, Cimaz R. How Should We Classify Kawasaki Disease? Frontiers in Immunology 2018;9. https://doi.org/10.3389/fimmu.2018.02974.
47. [47] Wang L, Zhang S, Ma J, Ni J, Wang J, Li X, et al. Kawasaki Disease- Management Strategies Given Symptoms Overlap to COVID-19: A Review. Journal of Nepal Medical Association 2021;59. https://doi.org/10.31729/jnma.5698.
48. [48] Mercier J-C, Ouldali N, Melki I, Basmaci R, Levy M, Titomanlio L, et al. Severe acute respiratory syndrome coronavirus 2-related multisystem inflammatory syndrome in children mimicking Kawasaki disease. Archives of Cardiovascular Diseases 2021;114:426–33. https://doi.org/10.1016/j.acvd.2021.04.005.
49. [49] Cattalini M, della Paolera S, Zunica F, Bracaglia C, Giangreco M, Verdoni L, et al. Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. Pediatric Rheumatology 2021;19:29. https://doi.org/10.1186/s12969-021-00511-7.
50. [50] Marzano AV, Cassano N, Moltrasio C, Verdoni L, Genovese G, Vena GA. Multisystem Inflammatory Syndrome in Children Associated with COVID-19: A Review with an Emphasis on Mucocutaneous and Kawasaki Disease-Like Findings. Dermatology 2022;238:35–43. https://doi.org/10.1159/000515449.
51. [51] Guo MM-H, Yang KD, Liu S-F, Kuo H-C. Number of Kawasaki Disease Admissions Is Associated with Number of Domestic COVID-19 and Severe Enterovirus Case Numbers in Taiwan. Children 2022;9:149. https://doi.org/10.3390/children9020149.
52. [52] Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nature Reviews Immunology 2020;20:271–2. https://doi.org/10.1038/s41577-020-0312-7.
53. [53] Chen C-H, Lin L-Y, Yang KD, Hsieh K-S, Kuo H-C. Kawasaki disease with G6PD deficiency—Report of one case and literature Review. Journal of Microbiology, Immunology and Infection 2014;47:261–3. https://doi.org/10.1016/j.jmii.2012.05.002.